COLL News and Press, Collegium Pharmaceutical Inc. From 01/17/24

2024-01-17 19:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-13 10:30:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...

2024-01-08 08:31:52 ET Summary The healthcare sector was flat in 2023 year as a result of some unique issues. Drug price regulation will be a serious challenge for the sector this year. Defensive healthcare industry groups should do well during the first half and biotechnology...

2024-01-05 14:30:17 ET More on the markets SPY And QQQ: Fundamentals Remain Strong, Buying The Dip Verily Volatility: SPY Puts Are Cheap And The Market Is Selling Off The Market Looks Poised To Make New Highs In 2024 ETFs attract $597B in 2023 marking the fou...

2024-01-03 08:15:14 ET More on Collegium Pharmaceutical Collegium Pharmaceutical: Delivering On Promises Collegium Pharmaceutical Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Collegium Pharmaceutical Historical earnings data for Collegium P...

– Product Revenues, Net Expected in the Range of $580.0 Million to $595.0 Million – – Adjusted Operating Expenses* Expected in the Range of $120.0 Million to $125.0 Million – – Adjusted EBITDA* Expected in the Range of $380.0 Million to $395.0 ...

2023-11-30 01:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

STOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the judgment of the Patent Trial and Appeal Board (PTAB) in...

2023-11-09 08:42:26 ET More on Collegium Pharmaceutical Collegium Pharmaceutical: Delivering On Promises Collegium Pharmaceutical: Pipeline Continues As Share Buyback Initiates Collegium pain med Nucynta gets US market exclusivity extension For further detail...

2023-11-07 22:15:13 ET Collegium Pharmaceutical, Inc. (COLL) Q3 2023 Earnings Conference Call November 7, 2023 04:30 PM ET Company Participants Christopher James - Vice President, Investor Relations Joe Ciaffoni - President and CEO Colleen Tupper - Chief Financia...